
Dr Virginia A Pedicord
Group Leader and Principal Investigator, Department of Medicine and Cambridge Institute of Therapeutic Immunology & Infectious Disease
Co-Director, Cambridge Immunology Network
About me
Dr Pedicord received her PhD in Immunology and Microbial Pathogenesis from Cornell University, studying T cell biology and cancer immunotherapy under the supervision of Dr James P Allison at Memorial Sloan Kettering Cancer Center. She then completed postdoctoral training in mucosal immunology and enteric infection at the Rockefeller University before starting her own research group at the University of Cambridge.
In Cambridge, she has pioneered new functional approaches to microbiome research and generated key bioinformatics and biological tools to enable mechanistic studies of how the gut microbiome modulates health and disease. Her research group aims to decipher what the genomically encoded functions and metabolic outputs of the microbiome are and how these affect host physiology. Leveraging key clinical collaborations alongside bioinformatics, multi-omics and experimental models, her research spans numerous disease and health states, including irritable bowel syndrome, Crohn’s disease, multiple cancer types, Alzheimer’s disease, enteric infection and autism spectrum disorders.
Course
Awards
Wellcome Trust Career Development Award
American Association of Immunologists Careers in Immunology Fellowship
Roles
Group Leader and Principal Investigator, Department of Medicine and Cambridge Institute of Therapeutic Immunology & Infectious Disease
Co-Director, Cambridge Immunology Network
Publications
Hexa-acylated lipopolysaccharides from the gut microbiota enhance cancer immunotherapy responses(Opens in a new window), 2024, preprint, bioRxiv. Nature Microbiology, 2025, accepted.
Integrating functional metagenomics to decipher microbiome–immune interactions(Opens in a new window), 2024, Immunology & Cell Biology, 102(8), 680–691.
Enterocloster clostridioformis induces host intestinal epithelial responses that protect against Salmonella infection(Opens in a new window), 2023, preprint, bioRxiv. Microbiome, 2025, accepted.
Identification of gut microbial species linked with disease variability in a widely used mouse model of colitis(Opens in a new window), 2022, Nature Microbiology, 7, 590–599.
The Mouse Gastrointestinal Bacteria Catalogue enables translation between the mouse and human gut microbiotas via functional mapping(Opens in a new window), 2022, Cell Host & Microbe, 30(1), 124–138.